Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Greenphire and IMS Health Announce Strategic Integration

Published: Friday, June 21, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
Launch of strategic integration of eClinicalGPS and GrantPlan.

Greenphire has announced the launch of a strategic integration of Greenphire’s eClinicalGPS, the leading global investigator payment technology, with IMS Health’s GrantPlan, the leading benchmarking and contracting tool for global clinical site grants.

Together, the two technologies will enable the companies’ clients to access valuable analytics that have previously not been available or near impossible to aggregate.

Clients will be able to compare benchmarked data against both actual contracted amounts and actual expenses incurred, and precisely evaluate the performance of third parties responsible for negotiating contracts.

Clients will also be able to proactively identify and mitigate unplanned expenses throughout a specific study and to better anticipate actual budget variance in future trials.

The product integration will also allow for a quick and easy transition from the planning and contracting phase of a clinical trial to the trial’s execution by automating data-sharing throughout the clinical financial lifecycle.

For site contracting processes, data will seamlessly flow in a closed loop from the benchmarking and planning phase, to the contracting and negotiation phase, through to the execution of payments to sites and payment data aggregation for the purposes of Sunshine Act and other required reporting.

Linda Drumright, General Manager of Clinical Trial Optimization Solutions at IMS Health, said, “This collaboration with Greenphire will build an integration between two of the industry’s leading clinical financial technologies, enabling sponsors to gain further control over the costs associated with clinical trials, from budgeting and planning to payment execution, and to automatically access the information they need to keep their trials on track and remain compliant with global regulations.”

“We are very excited to launch this integration with IMS Health’s GrantPlan to drive additional value for our respective clients,” said Greenphire Founder & CEO Sam Whitaker, “Our combined technologies will provide clinical trial managers with the tools they need to stay informed about how actual study expenses are lining up with budgets, in real-time, and accurately project future expenses against budgets. We are striving to not only further automate the contracting, negotiation and payment management environment, but also equip our clients with the data needed to make informed decisions that will enable them to course-correct and take action in the present to control costs at future points in time.”

IMS Health’s GrantPlan is the industry’s leading benchmarking tool for current global clinical grant costs. It is the world’s largest database of such costs, containing extensive cost data at the cost per procedure, cost per visit, and cost per patient levels from around the world, including emerging countries.

IMS Health’s GrantPlan is the most recognized product representing current fair market value for investigator grant costs and is the world’s first 100% web-based online benchmarking and negotiation tool for international clinical grants.

Greenphire’s eClinicalGPS facilitates accurate payment calculation, manages complex payment approval processes, and automates payment execution in local currencies from sponsors and CROs to all investigators, sites and other vendors involved in a clinical trial on a global basis.

Using an intelligent web-based clinical payment platform, the eClinicalGPS dramatically reduces the time and resources needed to calculate, approve and deliver site payments in local currency and produce complex reports, including aggregated reports needed to make disclosures required by the Sunshine Act and other global transparency laws.

The eClinicalGPS turns a historically manual and tactical task‐driven administrative process into an automated process that provides strategic value to Greenphire's clients.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Greenphire Awards $35,000 to Three Health and Wellness Nonprofits
NO MORE received a donation of $20,000 to further its mission to end domestic violence and sexual assault.
Wednesday, June 25, 2014
Greenphire Appoints Senior Director of Business Development in Europe
Alex Livingstone brings more than 12 years of eClinical software, pharmaceutical and biotechnology industry experience to the company.
Thursday, October 10, 2013
Greenphire Named One of the Fastest-Growing U.S Companies
The company has been ranked in the 2013 Inc. Magazine 500 list of the fastest-growing private companies in the U.S.
Wednesday, August 21, 2013
Greenphire and Ernst & Young Announce Strategic Partnership
Partnership will combine eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young.
Wednesday, July 10, 2013
Greenphire and Oracle to Work Together
New partnership to automate clinical trial planning, budgeting and payments.
Tuesday, June 25, 2013
Greenphire's John Samar Named CFO of the Year Finalist
The Philadelphia Business Journal awards honour professionals who have displayed outstanding performance in their roles as corporate financial leaders.
Wednesday, May 29, 2013
Greenphire CEO Selected as Finalist in Ernst & Young Awards
CEO Sam Whitaker has been selected as a finalist for the Ernst & Young Entrepreneur of the Year Awards 2013 in the Greater Philadelphia region.
Friday, May 17, 2013
Greenphire Announces New London Office
Plans to facilitate expansion in Europe.
Tuesday, May 07, 2013
Greenphire Appoints UK-based Global Product Manager
Appointment of Rory O’Hare to facilitate European growth.
Thursday, February 21, 2013
Greenphire Supports Proposed EU Legislation to Reduce Clinical Trial Administration
The proposed legislation expected to be enacted by 2016.
Friday, July 27, 2012
Greenphire Appoints Chief Commercial Officer
Appointment of John M Blakeley to the role of Chief Commercial Officer.
Thursday, July 12, 2012
Greenphire and Merge Healthcare Form Exclusive Partnership
Partnership to integrate clinical payment and EDC platforms.
Wednesday, May 09, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!